Low-income women and use of prescribed contraceptives in the context of full health insurance coverage in France, 2019.


Journal

Contraception
ISSN: 1879-0518
Titre abrégé: Contraception
Pays: United States
ID NLM: 0234361

Informations de publication

Date de publication:
05 2023
Historique:
received: 13 09 2022
revised: 23 01 2023
accepted: 30 01 2023
medline: 5 5 2023
pubmed: 10 2 2023
entrez: 9 2 2023
Statut: ppublish

Résumé

Major socioeconomic differences in contraceptive use are observed in high-income countries. Cost is often cited as a main factor to explain these differences but other barriers may also exist. Our aim was to compare prescribed contraceptive use among low-income and non-low-income women in a national context of full health insurance coverage. In the French national health insurance database, we selected all women (14.8 million) aged 15-49 years living in France in 2019. We compared the prevalence of use of each prescribed contraceptive between low-income and non-low-income women: oral contraceptives, copper intrauterine devices (IUDs), the levonorgestrel intrauterine system (LNG-IUS), and implants. In the study population, 11% had a low income. Fewer low-income women used prescribed contraceptives than non-low-income women (36% vs. 46%, p < 0.001). When using a contraceptive, low-income women used a different method: at 20-24 years old, they used less oral contraceptives (60% vs. 77%, p < 0.001) and more implants (22% vs. 9%, p < 0.001), while at 40-44 years, they used less levonorgestrel intrauterine systems (18% vs. 30%, p < 0.001). Even in a national context of free access to medical care for low-income women, they use less and different prescribed contraceptives than non-low-income women. These results could reflect barriers other than financial cost to the use of prescribed contraceptives by low-income women. Financial barriers need to be removed in order to increase contraceptive use. However, this may not be sufficient and further research should explore barriers that low-income women may encounter in accessing and choosing their contraception.

Identifiants

pubmed: 36758736
pii: S0010-7824(23)00036-7
doi: 10.1016/j.contraception.2023.109976
pii:
doi:

Substances chimiques

Levonorgestrel 5W7SIA7YZW
Contraceptives, Oral 0
Contraceptive Agents, Female 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109976

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Juliette Congy (J)

Institut National d'Etudes Démographiques, Ined, Sexual and Reproductive Health and Rights Unit - UR14, 9 cours des Humanités, Aubervilliers, France. Electronic address: juliette.congy@ined.fr.

Jean Bouyer (J)

Institut National d'Etudes Démographiques, Ined, Sexual and Reproductive Health and Rights Unit - UR14, 9 cours des Humanités, Aubervilliers, France; Université Paris-Saclay, UVSQ, Inserm, CESP, 16 avenue Paul Vaillant Couturier, Villejuif, France.

Elise de La Rochebrochard (E)

Institut National d'Etudes Démographiques, Ined, Sexual and Reproductive Health and Rights Unit - UR14, 9 cours des Humanités, Aubervilliers, France; Université Paris-Saclay, UVSQ, Inserm, CESP, 16 avenue Paul Vaillant Couturier, Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH